Stock report · Delisted · NYSE American
Chromocell Therapeutics Corporation (CHRO)
22.46USD Delisted Final close · Sep 2, 2025
CHRO no longer trades. Chromocell Therapeutics was delisted from the NYSE American in September 2025.
All prices on this page are historical. The last trade was on September 2, 2025, at $22.46.
CHRO stock price history
Final trading statistics
- Final close
- $22.46
- Final trading day
- Sep 2, 2025
- Market cap at delisting
- $8.90M
- Shares outstanding
- 6.60M
- Final 52-week range
- $0.45 – $54.29
- Avg. volume (final 3 mo.)
- 62,269
- All-time high
- $48.00 · Feb 2024
- All-time low
- $5.41 · Nov 2024
- Return since IPO
- -53.2%
- Beta
- —
- Book value / share
- −$6.79
- Price / book
- -3.31
About Chromocell Therapeutics Corporation
Chromocell Therapeutics Corporation was a clinical-stage biotech company developing pain treatments. It targeted the sodium ion channel NaV1.7 with blockers that act on the peripheral nervous system.
Its lead compound, CC8464, had finished Phase 1 trials for moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It was also developing CT2000, a topical treatment for acute and chronic eye pain, and CT3000 for post-surgical pain using nerve blocks.
The company renamed itself Channel Therapeutics Corporation in November 2024. Founded in 2002 and based in Freehold, New Jersey, it was delisted from the NYSE American in September 2025, with the last trade on September 2, 2025 at $22.46.
- Exchange (former)
- NYSE American
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Freehold, NJ
- Employees
- 4
- IPO date
- February 16, 2024
- Delisted
- September 2, 2025
- SEC CIK
- 1919246
Chromocell Therapeutics financials before the delisting
The last 5 fiscal years Chromocell Therapeutics reported as a public company, fiscal year ending December.
CHRO revenue and net income
CHRO earnings per share
CHRO annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | −$8.0M | — |
| FY2023 | $0.00 | −$7.4M | — |
| FY2023 | $0.00 | −$7.4M | — |
| FY2022 | $0.00 | −$2.5M | — |
| FY2022 | $0.00 | −$2.5M | — |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Chromocell Therapeutics stock FAQ
What happened to Chromocell Therapeutics stock?
Chromocell Therapeutics was delisted from the NYSE American in September 2025. The final close was $22.46 on September 2, 2025.
Can I still buy CHRO stock?
No. CHRO is no longer listed on the NYSE American or any other U.S. exchange; it was removed on September 2, 2025.
What was the last price of CHRO?
CHRO last closed at $22.46 on September 2, 2025, which valued the company at about $8.90M.
How did Chromocell Therapeutics do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Chromocell Therapeutics reported revenue of $0.00 and net income of −$8.0M.
When did Chromocell Therapeutics go public?
Chromocell Therapeutics shares started trading on February 16, 2024.
CHRO no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.